このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD

2026年9月16日 更新者:Xijing Hospital

Safety and Efficacy of rTMS on Individualized dlPFC-NAcc Functional Connectivity in Adolescents With Depression and Anhedonia: a Randomized Clinical Trial

This study evaluates a schedule of precise repetitive transcranial magnetic stimulation for depressive adolescent with anhedonia. In this randomized controlled trial, half of the participants will receive repetitive transcranial magnetic stimulation, and the other will receive sham stimulation.

調査の概要

詳細な説明

Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression among adult. The approved method for treatment is 10Hz stimulation over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been successful for many people with treatment-resistant depression. However, a large percentage of adolescents suffering from major depressive disorder (MDD) do not adequately benefit from currently available treatments. One of the limitations is concerns about the safety and efficacy of antidepressant. Recently, researchers have aggressively pursued better treatment strategy such as rTMS to improve adolescent depression with some preliminary success. This study intends to further explore the safety and efficacy of rTMS in the treatment for adolescent major depressive disorder with anhedonia. This study will also look at the change in neuroimaging biomarkers associated with this treatment.

研究の種類

介入

入学 (実際)

88

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Shaanxi
      • Xi'an、Shaanxi、中国、710032
        • Xijing Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

13年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or female, 13 to 18 years of age.
  • According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE).
  • Meet the threshold on the total HAMD17 score of >/=17 at both screening and baseline visits (Day -7 and Day 0).
  • Meet the threshold on the total SHAPS score of >/=20 at both screening and baseline visits (Day -7 and Day 0).
  • Not take any antidepressants for two or more weeks before screening.
  • In good general health, as ascertained by medical history.
  • After fully understanding the treatment of transcranial magnetic stimulation, willing to cooperate with the treatment actively and able to provide informed consent.

Exclusion Criteria:

  • Current diagnosis of a Substance Use Disorder, with the exception of nicotine and caffeine dependence.
  • Current diagnosis of mental disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is clinically unstable, and/or the focus of the participant's treatment for the past six months or more).
  • History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes.
  • Any other Mental Disorders, Personality Disorders, Intellectual Disability, which at screening is clinically predominant to their MDD.
  • Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results.
  • Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
  • Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.
  • History of electronic instrument or metal in the head or skull.
  • History of epilepsy.
  • History of cardiovascular disease or cardiac event.
  • History of OCD.
  • History of autism spectrum disorder.
  • History of rTMS exposure.
  • Other situations judged by the researchers to be unsuitable for the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:rTMS Active

Blinded Active TMS coil. Active repetitive Transcranial Magnetic Stimulation (rTMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)

Compare active coil with sham coil.

他の名前:
  • セルトラリン
  • TMS
偽コンパレータ:rTMS Sham

Blinded Sham TMS coil. Sham Transcranial Magnetic Stimulation (TMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)

Compare active coil with sham coil.

他の名前:
  • セルトラリン
  • TMS

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percent Change in the Snaith-Hamilton Pleasure Scale (SHAPS)Score From Pre-treatment to 8-weeks
時間枠:Pre-treatment and 8-weeks post treatment

A 14 item self-assessment questionnaire used to measure the severity of anhedonia symptom in patients with mood disorders. Scale range - 14 to 56 with higher score indicative of greater anhedonia symptomology.

Pre-treatment and 8-weeks post treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Score of the Hamilton Rating Scale for Depression (HAM-17)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

A provider administered questionnaire used to assess remission and recovery from depression. Scale range - 0 to 52 with higher score indicative of greater depressive symptomology. Additional collection time points were prespecified; only those time points for which data were collected are reported.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Montgomery Asberg Depression Rating Scale (MADRS)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

A diagnostic questionnaire used to measure the severity of depressive symptoms. Scale range - 0 to 60 with higher score indicative of greater depressive symptomology.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Chinese version of Temporal Experience of Pleasure Scale(CV-TEPS)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

A 20 item self-assessment questionnaire, eleven items used to measure anticipatory anhedonia, and nine items used to evaluate consummatory anhedonia. Scale range - 0 to 140 with lower score indicative of greater anhedonia symptomology.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Chinese version of Beck Scale for Suicide Ideation(BSI-CV)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

A 19 item questionnaire used to evaluate the severity of suicidal ideation. The scale includes two subscales of suicidal ideation (Current suicidal ideation, BSI-C) and suicidal ideation (Suicidal ideation at one's worst point, BSI-W) in the last week. Scale range - 0 to 38, the higher the score of the subscale, the higher the level of suicidal ideation in the last week or the most serious.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Insomnia Severity Index Scale (ISI)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

The questionnaire consists of seven items: the severity of insomnia symptoms, the satisfaction of sleep patterns, the effects of insomnia on daytime function, the effects of insomnia on subjects' quality of life, and the degree of worry or depression caused by insomnia. Scale range - 0 to 28 with higher score indicative of greater Insomnia symptomology.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Clinical Global Impression (CGI)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

The questionnaire used to evaluate the clinical efficacy, it includes three parts: severity of illness (SI), global improvement (GI) and effect index (EI). With higher score indicative of more serious disease and worse effect.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Score of the Snaith-Hamilton Pleasure Scale (SHAPS)
時間枠:Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)

A 14 item self-assessment questionnaire used to measure the severity of anhedonia symptom in patients with mood disorders. Scale range - 14 to 56 with higher score indicative of greater anhedonia symptomology.

Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
Change From Baseline Functional Connectivity to 15-days Post-treatment
時間枠:Time Frame: Pre-treatment, immediately post-treatment (on day 15)

We will assess change in resting state fMRI functional connectivity of the nucleus accumbens to the Dorsolateral Prefrontal Cortex and within the reward-related circuits

Time Frame: Pre-treatment, immediately post-treatment (on day 15)

その他の成果指標

結果測定
メジャーの説明
時間枠
A digital tool named THINC-it® to help assess cognitive functioning
時間枠:Time Frame: Pre-treatment to 1 week and 15days, 4 weeks, 6 weeks and 8 weeks post-treatment

THINC-it® is a screening tool designed to measure cognition, is based on a combination of specific (traditional) neuropsychological tests assessing cognitive functioning, in conjunction with a patient-reported questionnaire.

Time Frame: Pre-treatment to 1 week and 15days, 4 weeks, 6 weeks and 8 weeks post-treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年2月12日

一次修了 (実際)

2024年7月31日

研究の完了 (実際)

2024年7月31日

試験登録日

最初に提出

2022年9月13日

QC基準を満たした最初の提出物

2022年9月14日

最初の投稿 (実際)

2022年9月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月16日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • KY20222165-F-1

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する